Modulation of non-coding RNAs by resveratrol in ovarian cancer cells: In silico analysis and literature review of the anti-cancer pathways involved

J Tradit Complement Med. 2020 Mar 4;10(3):217-229. doi: 10.1016/j.jtcme.2020.02.006. eCollection 2020 May.

Abstract

Background and aim: Non-coding RNAs control cell functioning through affecting gene expression and translation and their dysregulation is associated with altered cell homeostasis and diseases, including cancer. Nutraceuticals with anti-cancer therapeutic potential have been shown to modulate non-coding RNAs expression that could impact on the expression of genes involved in the malignant phenotype.

Experimental procedure: Here, we report on the microarray profiling of microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) and on the associated biochemical pathways and functional processes potentially modulated in OVCAR-3 ovarian cancer cells exposed for 24 h to Resveratrol (RV), a nutraceutical that has been shown to inhibit carcinogenesis and cancer progression in a variety of human and animal models, both in vitro and in vivo. Diana tools and Gene Ontology (GO) pathway analyses along with Pubmed literature search were employed to identify the cellular processes possibly affected by the dysregulated miRNAs and lncRNAs.

Results and conclusion: The present data consistently support the contention that RV could exert anti-neoplastic activity via non-coding RNAs epigenetic modulation of the pathways governing cell homeostasis, cell proliferation, cell death and cell motility.

Keywords: Autophagy; Cancer; Cell metabolism; EMT, Epithelial to Mesenchymal Transition; Epigenetics; GO, Gene Ontology; Nutraceutical; RV, Resveratrol; TCGA, The Cancer Genome Atlas; Warburg effect; lncRNA, long non-coding RNA; miRNA, microRNA.